We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -4.08% | 23.50 | 22.00 | 25.00 | 4,000 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 1.47M | -6.15M | -0.0830 | -2.95 | 18.16M |
TIDMONC
RNS Number : 8682L
Oncimmune Holdings PLC
15 September 2021
15 September 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Block Listing Six Monthly Return
Oncimmune makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements in respect of Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans (the "Share Option Plans").
Name of applicant: Oncimmune Holdings plc Name of scheme: Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans --------------------------------- Period of return: 16 March 2021 to 15 September 2021 --------------------------------- Balance of unallotted securities under scheme(s) from previous return: 5,830,154 --------------------------------- Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0 --------------------------------- Less: Number of securities issued/allotted under scheme(s) during period: 24,409 --------------------------------- Equals: Balance under scheme(s) not yet issued/allotted at end of period: 5,805,745 ---------------------------------
For further information:
Oncimmune Holdings plc
Ron Kirschner, Company Secretary
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, James Hornigold
+44 (0)20 3829 5000
Singer Capital Markets (Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Nigel Birks
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRDKPBKKBKDOCD
(END) Dow Jones Newswires
September 15, 2021 06:08 ET (10:08 GMT)
1 Year Oncimmune Chart |
1 Month Oncimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions